Annual Meeting

Exploring cell surface changes in cancer

Jim Wells will speak during the Molecular & Cellular Proteomics session at Discover BMB
Chloe Kirk
Feb. 28, 2023

Jim Wells’ research has spanned biotech, academia and founding a company. He’s determined that whatever he does, it doesn’t feel like “punching the clock.”

Focusing on how cell surfaces change in response to health and disease, Wells uses his seminal work in protein engineering to explore drug development targets through protein mutagenesis.

Jim Wells
Jim Wells

“It’s important to me that my work ticks two critical boxes,” he said. “One is that this lab would be a great place to grow as a scientist, and the second is the work has to be fun.”

Raised in the San Francisco Bay Area, where he was inspired by enzymology researchers such as Daniel Koshland, Wells went to Washington State University for his Ph.D. to work under Ralph Yount who, he said, “taught me most of the things I know today, especially biochemistry and protein modification.”

Eighteen months into his postdoc at Stanford, “I realized I really enjoyed gene structure and function, and this amazing new technology called site-directed mutagenesis was just published,” Wells said. “I thought, ‘wow, this could be really amazing to apply to proteins.’”

Recombinant DNA studies were at such an early stage that Wells knew he wasn’t going to find an academic job to support this research. That’s when a friend introduced him to a company at the forefront of applying recombinant DNA for commercial use: Genentech.

At Genentech, Wells and his group engineered the first gain-of-function enzymes, growth factors and antibodies by site-directed mutagenesis. “I thought I’d be there three years to learn the technologies,” he said, “and ended up staying 16 years.”

Wells went on to start his own company, Sunesis Pharmaceuticals, before he moved in 2005 to the University of California, San Francisco, where he is a professor of chemistry.

Developing antibodies from cancer markers

Jim Wells’ work focuses on changing cell surface proteomics in changing cell health and diseases, most notably in cancers. He breaks his research into four projects: What’s Up, What’s Cut, All in the Neighborhood and Cell Portal.

The What’s Up project is centered around new blooms of proteins that appear specifically in cancerous cells, and the lab has recently published a new tool to label these blooms of proteins.

What’s Cut looks at the What’s Up project with another level of resolution. Here, the team looks at posttranslational modifications, such as glycosylation or proteolysis, tagging those proteins to find out what targets are being modified, and then makes antibodies that can attack those targets; they published recently on targeting RAS-driven cancers.

The All in the Neighborhood project switches gears and studies how protein complexes change on a cell’s surface during cancer.

The Cell Portal project examines how entire peptides change between normal and cancerous cells to engineer antibodies targeting cancerous peptide complexes, as the team recently reported in the Journal of the American Cancer Society.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Chloe Kirk

Chloe Kirk is working toward her Ph.D. in biochemistry and molecular biology at the University of Miami. Her interests are science research, communication and outreach.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

ASBMB names 2025 fellows
Announcement

ASBMB names 2025 fellows

Feb. 17, 2025

American Society for Biochemistry and Molecular Biology honors 24 members for their service to the society and accomplishments in research, education, mentorship, diversity and inclusion and advocacy.

When Batman meets Poison Ivy
Science Communication

When Batman meets Poison Ivy

Feb. 13, 2025

Jessica Desamero had learned to love science communication by the time she was challenged to explain the role of DNA secondary structure in halting cancer cell growth to an 8th-grade level audience.

The monopoly defined: Who holds the power of science communication?
Essay

The monopoly defined: Who holds the power of science communication?

Feb. 12, 2025

“At the official competition, out of 12 presenters, only two were from R2 institutions, and the other 10 were from R1 institutions. And just two had distinguishable non-American accents.”

In memoriam: Donald A. Bryant
In Memoriam

In memoriam: Donald A. Bryant

Feb. 10, 2025

He was a professor emeritus at Penn State University who discovered how cyanobacteria adapt to far-red light and was a member of the American Society for Biochemistry and Molecular Biology for over 35 years.

 Yes, I have an accent — just like you
Science Communication

 Yes, I have an accent — just like you

Feb. 6, 2025

When the author, a native Polish speaker, presented her science as a grad student, she had to wrap her tongue around the English term “fluorescence cross-correlation microscopy.”

Professorships for Booker; scholarship for Entzminger
Member News

Professorships for Booker; scholarship for Entzminger

Feb. 3, 2025

Squire Booker has been appointed to two honorary professorships at Penn State University. Inayah Entzminger received a a BestColleges scholarship to support their sixth year in the biochemistry Ph.D. program at CUNY.